Tricyclic Sulfone RORγ Modulators for IL-17 Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are insufficient in addressing the unmet medical need for treating inflammatory and autoimmune diseases, particularly those involving dysregulated IL-17 production, such as psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, where RORγ modulation offers a promising therapeutic benefit.
Innovation Solution
Development of specific compounds that modulate RORγt activity, including those of the formula described, which can be used to diagnose, prevent, or treat various immune and inflammatory disorders by targeting the RORγ receptor pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used, then existing treatment protocols are maintained, but they are insufficient for treating inflammatory and autoimmune diseases involving dysregulated IL-17 production
Solution Approach 1:
The patent introduces novel chemical compounds with specific molecular structures (tricyclic sulfones) that represent a parameter change in therapeutic agents. These compounds target RORγt receptors to modulate IL-17 production, providing a new mechanism of action that improves therapeutic efficacy for inflammatory and autoimmune diseases where existing agents are insufficient.
2Reliability
If RORγt modulation is implemented, then therapeutic benefits are achieved in treating autoimmune and inflammatory diseases, but new compound development and validation are required
Solution Approach 1:
The patent performs preliminary action by providing a comprehensive framework including novel compound structures, synthetic methods, and preclinical validation data before clinical application. The detailed description of synthesis protocols and characterization methods enables straightforward replication and manufacturing, reducing the barrier to translating RORγt modulation into therapeutic practice.
Data Source
AI summary
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.